March 24, 2023
A Phase 1, First-in-Human, Multicenter, Open-Label, Two Part Dose-Escalation and Cohort Expansion Study of Single-Agent ISB 1342 in Subjects with Previously Treated Multiple Myeloma
Select an appointment date and time from available spots listed below.